<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02150616</url>
  </required_header>
  <id_info>
    <org_study_id>ID 2013-0088V2A3D</org_study_id>
    <nct_id>NCT02150616</nct_id>
  </id_info>
  <brief_title>Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Breathing and Sleep</brief_title>
  <official_title>Patients With Pulmonary Hypertension or Interstitial Lung Disease Travelling to Altitude - Effect of Nocturnal Oxygen Therapy on Breathing and Sleep</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of travelling to moderate altitude and
      of nocturnal oxygen therapy during a stay at moderate altitude on breathing and sleep of
      patients with pulmonary hypertension or with interstitial lung disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with pulmonary hypertension or with interstitial lung disease living below 800 m
      will be invited to participate in a randomized, cross-over field trial evaluating the
      hypotheses that: a), breathing and sleep during a 2 day sojourn at moderate altitude are
      impaired in comparison to low altitude; b), breathing and sleep during a 2 day sojourn at
      moderate altitude are improved by nocturnal oxygen therapy compared to room air (sham oxygen)
      administered during nights at altitude. Outcomes will be assessed at low altitude (Zurich,
      490 m, baseline), and during 2 study periods of 2 days each spent at moderate altitude (St.
      Moritz Salastrains, 2048 m), separated by a wash-out period of at least 2 weeks spent at low
      altitude (&lt;800 m). The order of stays at the different altitudes and of the treatments will
      be randomized.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean nocturnal oxygen saturation measured by pulse oximetry</measure>
    <time_frame>Approximately 8 hours (during the first night at 2048 m)</time_frame>
    <description>Difference in mean nocturnal oxygen saturation between measurements at 2048 m (altitude) and 490 m (baseline); and between the oxygen and sham oxygen treatment periods at 2048 m.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apnea/hypopnea index measured by polysomnography</measure>
    <time_frame>Approximately 8 hours (during the first night at 2048 m)</time_frame>
    <description>Difference in apnea/hypopnea index between measurements at 2048 m (altitude) and 490 m (baseline); and between the oxygen and sham oxygen treatment periods at 2048 m.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean nocturnal oxygen saturation measured by pulse oximetry</measure>
    <time_frame>Approximately 8 hours (during the second night at 2048 m)</time_frame>
    <description>Difference in mean nocturnal oxygen saturation between measurements at 2048 m (altitude) and 490 m (baseline); and between the oxygen and sham oxygen treatment periods at 2048 m.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apnea/hypopnea index measured by polygraphy</measure>
    <time_frame>Approximately 8 hours (during the second night at 2048 m)</time_frame>
    <description>Difference in apnea/hypopnea index between measurements at 2048 m (altitude) and 490 m (baseline); and between the oxygen and sham oxygen treatment periods at 2048 m.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality visual analog scale score</measure>
    <time_frame>Approximately 8 hours (during the first night at 2048 m)</time_frame>
    <description>Difference in subjective sleep quality between visual analog scale measurements at 2048 m (altitude) and 490 m (baseline); and between the oxygen and sham oxygen treatment periods at 2048 m.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychomotor vigilance test reaction time</measure>
    <time_frame>Approximately at 10 a.m. on the second day at 2048 m</time_frame>
    <description>Difference in reaction time between measurements at 2048 m (altitude) and 490 m (baseline); and between the oxygen and sham oxygen treatment periods at 2048 m.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe hypoxemia</measure>
    <time_frame>Approximately 72 hours, Day 1 to 3 at 2048 m</time_frame>
    <description>Number of participants in whom arterial oxygen saturation measured by pulse oximetry is less than 75% for more than 30 min during the sojourn at 2048 m (altitude) and 490 m (baseline); and during the oxygen and sham oxygen treatment periods at 2048 m.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective sleep quality visual analog scale score</measure>
    <time_frame>Approximately 8 hours (during the second night at 2048 m)</time_frame>
    <description>Difference in subjective sleep quality between visual analog scale measurements at 2048 m (altitude) and 490 m (baseline); and between the oxygen and sham oxygen treatment periods at 2048 m.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Precapillary Pulmonary Hypertension</condition>
  <condition>Interstitial Lung Disease</condition>
  <arm_group>
    <arm_group_label>Moderate altitude sojourn</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sojourn at moderate altitude (2048 m)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low altitude sojourn</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sojourn at low altitude (490 m, baseline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxygen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham oxygen (room air)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Moderate altitude sojourn</intervention_name>
    <description>Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days</description>
    <arm_group_label>Moderate altitude sojourn</arm_group_label>
    <arm_group_label>Low altitude sojourn</arm_group_label>
    <arm_group_label>Oxygen</arm_group_label>
    <arm_group_label>Sham oxygen (room air)</arm_group_label>
    <other_name>Moderate altitude sojourn at 2048 m for 2 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low altitude sojourn</intervention_name>
    <description>Low altitude baseline evaluations will be performed during a stay at Zurich (490)</description>
    <arm_group_label>Moderate altitude sojourn</arm_group_label>
    <arm_group_label>Low altitude sojourn</arm_group_label>
    <arm_group_label>Oxygen</arm_group_label>
    <arm_group_label>Sham oxygen (room air)</arm_group_label>
    <other_name>Low altitude sojourn at 490 m (Zurich) for 1.5 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m</description>
    <arm_group_label>Moderate altitude sojourn</arm_group_label>
    <arm_group_label>Low altitude sojourn</arm_group_label>
    <arm_group_label>Oxygen</arm_group_label>
    <arm_group_label>Sham oxygen (room air)</arm_group_label>
    <other_name>Nocturnal nasal oxygen administration during stay at 2048 m</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham oxygen (room air)</intervention_name>
    <description>Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m</description>
    <arm_group_label>Moderate altitude sojourn</arm_group_label>
    <arm_group_label>Low altitude sojourn</arm_group_label>
    <arm_group_label>Oxygen</arm_group_label>
    <arm_group_label>Sham oxygen (room air)</arm_group_label>
    <other_name>Nocturnal nasal room air administration</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Precapillary pulmonary hypertension, or interstitial lung disease.

          -  New York Heart Association class 2-3.

          -  Residence at low altitude (&lt;800m).

        Exclusion Criteria:

          -  Unstable or exacerbated condition

          -  Very severe pulmonary hypertension or interstitial lung disease, New York Heart
             Association class 4

          -  requirement for oxygen therapy at low altitude residence

          -  hypoventilation

          -  more than mild or unstable cardiovascular disease

          -  use of drugs that affect respiratory center drive

          -  internal, neurologic or psychiatric disease that interfere with protocol compliance
             including current heavy smoking (&gt;20 cigarettes per day), inability to perform 6 min
             walk test.

          -  previous intolerance to moderate altitude (&lt;2600m).

          -  Exposure to altitudes &gt;1500m for &gt;2 days within the last 4 weeks before the study.

          -  Pregnant or nursing patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konrad E Bloch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Zürich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Konrad E Bloch, MD</last_name>
    <phone>+41 44 255 3828</phone>
    <email>konrad.bloch@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tsogyal D Latshang, MD</last_name>
    <phone>+41 44 255 3828</phone>
    <email>tsogyal.latshang@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Pulmonary Division</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konrad E Bloch, MD</last_name>
      <phone>+41 44 255 3828</phone>
      <email>konrad.bloch@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Tsogyal D Latshang, MD</last_name>
      <phone>+41 44 255 3828</phone>
      <email>tsogyal.latshang@usz.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Konrad E Bloch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2014</study_first_submitted>
  <study_first_submitted_qc>May 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary hypertension</keyword>
  <keyword>Interstitial lung disease</keyword>
  <keyword>Pulmonary fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

